Citations

Clear

1134 citation(s) found for "Yan, Su".

Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis
Qu, Wenchun , Engelberg-Cook, Erica , Yan, Dan , Siddik, Abu Bakar , Bu, Guojun , Allickson, Julie, Kubrova, Eva , Hare, Joshua M. , Pascual, Jorge M., Nayfeh, Tarek , Saadi, Samer , Durvasula, Ravindra, Richards, Elaine M. , Sanfilippo, Fred , Siddik, Abu Bakar , Allickson, Julie G, Hare, Joshua M , Kurtzberg, Joanne , Mallea, Jorge M. , Durvasula, Ravindra V, Bu, Guojun , Nayfeh, Tarek , Saadi, Samer , Wang, Zhen , Caplan, Arnold I. , Ricordi, Camillo , Pepine, Carl J. , Rodríguez, Ricardo López , March, Keith L.

Mayo Clinic

Stem Cells Translational Medicine | April 29, 2022 | Volume: 11 | Issue: 7 | Pages: 688-703

10.1093/stcltm/szac032 | PMID 35640138 Get It

Abstract MSC (a.k.a. mesenchymal stem cell or medicinal signaling cell) cell therapies show promise in decreasing mortality in acute respiratory distress syndrome (ARDS) and suggest benefits in treatment of COVID-19-related ARDS. We performed a meta-analysis of published trials assessing the efficacy and adverse events (AE) rates of MSC cell therapy in individuals hospitalized for COVID-19. Systematic searches were performed in multiple databases through November 3, 2021. Reports in all languages, including randomized clinical trials (RCTs), non-randomized interventional trials, and uncontrolled trials, were included. Random effects model was used to pool outcomes from RCTs and non-randomized interventional trials. Outcome measures included all-cause mortality, serious adverse events (SAEs), AEs, pulmonary function, laboratory, and imaging findings. A total of 736 patients were identified from 34 studies, which included 5 RCTs (n = 235), 7 non-randomized interventional trials (n = 370), and 22 uncontrolled comparative trials (n = 131). Patients aged on average 59.4 years and 32.2% were women. When compared with the control group, MSC cell therapy was associated with a reduction in all-cause mortality (RR = 0.54, 95% CI: 0.35-0.85, I 2 = 0.0%), reduction in SAEs (IRR = 0.36, 95% CI: 0.14-0.90, I 2 = 0.0%) and no significant difference in AE rate. A sub-group with pulmonary function studies suggested improvement in patients receiving MSC. These findings support the potential for MSC cell therapy to decrease all-cause mortality, reduce SAEs, and improve pulmonary function compared with conventional care. Large-scale double-blinded, well-powered RCTs should be conducted to further explore these results.
Predictive metabolic networks reveal sex‐ and APOE genotype‐specific metabolic signatures and drivers for precision medicine in Alzheimer's disease
Chang, Rui , Trushina, Eugenia , Zhu, Kuixi , Zaidi, Syed Shujaat Ali , Lau, Branden M, Moein, Sara, He, Qianying, Alamprese, Melissa , Vagnerova, Barbora, Tang, Andrew, Vijayan, Ramachandran , Liu, Yan‐Yun , Saykin, Andrew J. , Young‐Pearse, Tracy L. , Saykin, Andrew J , Trushina, Eugenia , Kueider‐Paisley, Alexandra , Tang, Andrew, Vijayan, Ramachandran, Brinton, Roberta Dı́az , Kaddurah‐Daouk, Rima

Mayo Clinic

Alzheimer's & Dementia | April 28, 2022 | Volume: 19 | Issue: 2 | Pages: 518-531

10.1002/alz.12675 | PMID 35481667 Get It

Abstract Introduction Late‐onset Alzheimer's disease (LOAD) is a complex neurodegenerative disease characterized by multiple progressive stages, glucose metabolic dysregulation, Alzheimer's disease (AD) pathology, and inexorable cognitive decline. Discovery of metabolic profiles unique to sex, apolipoprotein E ( APOE ) genotype, and stage of disease progression could provide critical insights for personalized LOAD medicine. Methods Sex‐ and APOE ‐specific metabolic networks were constructed based on changes in 127 metabolites of 656 serum samples from the Alzheimer's Disease Neuroimaging Initiative cohort. Results Application of an advanced analytical platform identified metabolic drivers and signatures clustered with sex and/or APOE ɛ4, establishing patient‐specific biomarkers predictive of disease state that significantly associated with cognitive function. Presence of the APOE ɛ4 shifts metabolic signatures to a phosphatidylcholine‐focused profile overriding sex‐specific differences in serum metabolites of AD patients. Discussion These findings provide an initial but critical step in developing a diagnostic platform for personalized medicine by integrating metabolomic profiling and cognitive assessments to identify targeted precision therapeutics for AD patient subgroups through computational network modeling.
Central Nervous System Metabolism in Autism, Epilepsy and Developmental Delays: A Cerebrospinal Fluid Analysis
Brister, Danielle , Werner, Brianna, Gideon, Geoffrey, McCarty, Patrick J. , Lane, Alison L., Burrows, Brian T., McLees, Sallie E., Adelson, P. David , Arango, Jorge , Marsh, W., Flores, Angelea, Ly, Ngoc Han, Flood, Madison, Brown, Danni, Carpentieri, David , Jin, Yan , Gu, Haiwei , Frye, Richard E. , Marsh, William, Carpentieri, David , Frye, Richard E , Pankratz, Matthew T

Mayo Clinic

Metabolites | April 21, 2022 | Volume: 12 | Issue: 5 | Pages: 371

10.3390/metabo12050371 | PMID 35629876 Get It

Neurodevelopmental disorders are associated with metabolic pathway imbalances; however, most metabolic measurements are made peripherally, leaving central metabolic disturbances under-investigated. Cerebrospinal fluid obtained intraoperatively from children with autism spectrum disorder (ASD, n = 34), developmental delays (DD, n = 20), and those without known DD/ASD (n = 34) was analyzed using large-scale targeted mass spectrometry. Eighteen also had epilepsy (EPI). Metabolites significantly related to ASD, DD and EPI were identified by linear models and entered into metabolite–metabolite network pathway analysis. Common disrupted pathways were analyzed for each group of interest. Central metabolites most involved in metabolic pathways were L-cysteine, adenine, and dodecanoic acid for ASD; nicotinamide adenine dinucleotide phosphate, L-aspartic acid, and glycine for EPI; and adenosine triphosphate, L-glutamine, ornithine, L-arginine, L-lysine, citrulline, and L-homoserine for DD. Amino acid and energy metabolism pathways were most disrupted in all disorders, but the source of the disruption was different for each disorder. Disruption in vitamin and one-carbon metabolism was associated with DD and EPI, lipid pathway disruption was associated with EPI and redox metabolism disruption was related to ASD. Two microbiome metabolites were also detected in the CSF: shikimic and cis-cis-muconic acid. Overall, this study provides increased insight into unique metabolic disruptions in distinct but overlapping neurodevelopmental disorders.
The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
Tang, Hoi Ki Karen, Fung, Chi Yeung, Kumar, Shaji , Siu, Lisa L. P. , Ip, Ho Wan Alvin, Yip, Sze Fai, Lau, Ka Ngai Harry, Lau, Chi Kuen, Leung, Kwan Hung, Kho, B C S, Wong, Howard, Ngai, Cheong , Hwang, Yu Yan, Sim, Joycelyn, Kumar, Shaji K , Chim, Chor Sang , Morgan, Gareth J. , Lee, Harold , Wong, Howard, Hwang, Yu‐Yan , Kwong, Yok‐Lam , Chim, Chor Sang

Mayo Clinic

Therapeutic Advances in Hematology | April 18, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/20406207221082043 | PMID 35465644 Get It

Introduction: Bortezomib has been reported to favourably impact the outcomes of t(4;14) and del(17p) in multiple myeloma (MM), but its impact on gain 1q (+1q) is unknown. Methods: To address this, 250 patients treated with bortezomib-based induction were analysed. All myeloma samples had fluorescence in situ hybridization (FISH) performed on CD138-sorted bone marrow aspirate, and plasma cells were analysed using DNA probes specific for the following chromosomal aberrations: del(13q14), del(17p), t(14;16), t(4;14), and +1q. Presence of +1q was defined as the presence of at least three copies of 1q21 at the cut off level of 20% of bone marrow plasma cells. Results: +1q identified in 167 (66.8%) and associated with t(4;14) and high lactate dehydrogenase (LDH). +1q was not associated with response rate but shorter event-free survival (EFS) (median EFS 35 vs 55 months, p = 0.05) and overall survival (OS) (median OS 74 vs 168 months, p = 0.00025). Copy number and clone size did not impact survival. Multivariate analysis showed +1q was an independent adverse factor for OS together with International Staging System (ISS)3, high LDH, del(17p) and t(4;14). When a risk score of 1 was assigned to each independent adverse factor, OS was shortened incrementally by a risk score from 0 to 4. Post-relapse/progression survival was inferior in those with +1q (median 60 vs 118 months, p = 0.000316). Autologous stem cell transplantation (ASCT) improved OS for those with +1q (median OS 96 vs 49 months, p = 0.000069). Conclusion: +1q is an adverse factor for OS in MM uniformly treated with bortezomib-based induction but was partially mitigated by ASCT. A risk scoring system comprising +1q, LDH, high-risk FISH, and ISS is a potential tool for risk stratification in MM.
Development of a Lyophilized Off-the-Shelf Mesenchymal Stem Cell-Derived Acellular Therapeutic
Driscoll, Julia , Yan, Irene K. , Patel, Tushar

Mayo Clinic

Pharmaceutics | April 13, 2022 | Volume: 14 | Issue: 4 | Pages: 849

10.3390/pharmaceutics14040849 | PMID 35456683 Get It

The therapeutic activities elicited by mesenchymal stem cells (MSC) are in part mediated through paracrine action by the release of extracellular vesicles (EV) and secreted proteins. Collectively, these MSC-derived factors, referred to as the secretome product (SP), are intrinsically therapeutic and represent an attractive alternative to cell-based therapies. Herein, we developed a lyopreservation protocol to extend the shelf-life of the MSC-SP without compromising the structural or functional integrity of the vesicular components. The SP isolated from normoxia- and anoxia-exposed MSC elicited protective effects in an in vitro model of oxidative injury and the bioactivity was retained in the lyophilized samples. Three separate formulations of MSC-SP were isolated by tangential flow filtration using sucrose, trehalose, and mannitol as lyoprotectant agents. The MSC-SPs were lyophilized using a manifold protocol and the structural and functional integrity were assessed. The trehalose formulation of SP exhibited the highest EV and protein recovery after manifold-based lyophilization. To facilitate development as a therapeutic, a shelf lyophilization protocol was developed which markedly enhanced the recovery of EV and proteins. In conclusion, lyophilization represents an efficient method to preserve the structural and functional integrity of the MSC-SP and can be used to develop an off-the-shelf therapeutic.
International consensus statement on allergy and rhinology: Olfaction
Patel, Zara M. , Holbrook, Eric H. , Turner, Justin H. , Adappa, Nithin D. , Albers, Mark W. , Altundağ, Aytuğ , Appenzeller, Simone , Costanzo, Richard M. , Croy, Ilona , Davis, Greg E. , Dehgani‐Mobaraki, Puya , Doty, Richard L. , Haehner, Antje , Hopkins, Claire , Hummel, Thomas , Jitaroon, Kawinyarat, Kern, Robert C. , Khanwalkar, Ashoke , Kobayashi, Masayoshi , Leopold, Donald A., Levy, Joshua M. , Marmura, Michael J. , Mclelland, Lisha, Miwa, Takaki , Moberg, Paul J., Mueller, Christian A. , Nigwekar, Sagar U. , O’Brien, Erin K. , Păunescu, Teodor G. , Philpott, Carl , Pinto, Jayant M. , Reiter, Evan R. , Schlosser, Rodney J. , Schwob, James E. , Seiden, Allen M., Smith, Timothy L. , Sowerby, Leigh J. , Tan, Bruce K. , Thamboo, Andrew , Wrobel, Bozena , Yan, Carol H. , Duffy, Valerie B , Goldstein, Bradley J , Gudis, David A , Haehner, Antje , Higgins, Thomas S , Hopkins, Claire , Huart, Caroline , Hummel, Thomas , Kern, Robert C , Khanwalkar, Ashoke R , Kobayashi, Masayoshi , Kondo, Kenji , Lane, Andrew P , Levy, Joshua M , Marmura, Michael J , O'Brien, Erin K , Paunescu, Teodor G , Pellegrino, Robert , Philpott, Carl , Roalf, David R , Rowan, Nicholas R , Schlosser, Rodney J , Schwob, James , Smith, Timothy L , Sowerby, Leigh , Yan, Carol , Holbrook, Eric H , Patel, Zara , Albers, Mark W , Adappa, Nithin D. , Gudis, David A. , Lechner, Matt , Rowan, Nicholas R. , Soler, Zachary M.

Mayo Clinic

International Forum of Allergy & Rhinology | April 3, 2022 | Volume: 12 | Issue: 4 | Pages: 327-680

10.1002/alr.22929 | PMID 35373533 Get It

Abstract Background The literature regarding clinical olfaction, olfactory loss, and olfactory dysfunction has expanded rapidly over the past two decades, with an exponential rise in the past year. There is substantial variability in the quality of this literature and a need to consolidate and critically review the evidence. It is with that aim that we have gathered experts from around the world to produce this International Consensus on Allergy and Rhinology: Olfaction (ICAR:O). Methods Using previously described methodology, specific topics were developed relating to olfaction. Each topic was assigned a literature review, evidence‐based review, or evidence‐based review with recommendations format as dictated by available evidence and scope within the ICAR:O document. Following iterative reviews of each topic, the ICAR:O document was integrated and reviewed by all authors for final consensus. Results The ICAR:O document reviews nearly 100 separate topics within the realm of olfaction, including diagnosis, epidemiology, disease burden, diagnosis, testing, etiology, treatment, and associated pathologies. Conclusion This critical review of the existing clinical olfaction literature provides much needed insight and clarity into the evaluation, diagnosis, and treatment of patients with olfactory dysfunction, while also clearly delineating gaps in our knowledge and evidence base that we should investigate further.
P29. DEVELOPING A LONG-TERM SURVIVAL HEMI-FACIAL VASCULARIZED COMPOSITE ALLOTRANSPLANTATION SWINE MODEL TO STUDY FACIAL NERVE REGENERATION
Mohan, Anita T. , Suchyta, Marissa , Bernard, Stacey, pederson, joanne, Yngsdal, Lisa, Benike, Amy, Bakri, Karim , Yan, María , Pederson, Joanne, Sharaf, Basel , Gibreel, Waleed , Amer, Hatem , Mardini, Samir

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 62-62

10.1097/01.gox.0000828472.60344.53 Get It

Understanding Suboptimal Response to Immune Checkpoint Inhibitors
Zhu, Mojun , Pedersen, Katrina S. , Foster, Nathan R. , Jaszewski, Brandy L., Liu, Xin , Hirdler, Jacob B. , An, Zesheng , Bekaii‐Saab, Tanios , Yan, Yiyi , Hubbard, Joleen H., Yoon, Harry H. , Revzin, Alexander , Fernández-Zapico, Martín E. , Overman, Michael J. , Dong, Haidong , Bekaii-Saab, Tanios S , Pedersen, Katrina , Zhang, Henan , Hálfdánarson, Þorvarður R. , Boland, Patrick M. , Hubbard, Joleen M. , Wee, Wen , McWilliams, Robert R. , Dong, Haidong

Mayo Clinic

Advanced Biology | March 27, 2022 | Volume: 7 | Issue: 4 | Pages: No page available

10.1002/adbi.202101319 | PMID 35343107 Get It

AbstractImmune checkpoint inhibitors (ICIs), as a novel class of anticancer therapy, can be more efficacious and less toxic than chemotherapy, but their clinical success is confined to certain tumor types. Elucidating their targets, mechanisms and scope of action, and potential synergism with chemotherapy and/or targeted therapies are critical to widen their clinical indications. Treatment response to an ICI targeting programmed death‐1 (anti‐PD‐1) is sought to be understood here by conducting a preplanned correlative analysis of a phase II clinical trial in patients with small bowel adenocarcinoma (SBA). The cytolytic capacity of circulating immune cells in cancer patients using a novel ex vivo cytotoxicity assay is evaluated, and the utility of circulating biomarkers is investigated to predict and monitor the treatment effect of anti‐PD‐1. Baseline expression of Bim and NKG7 and upregulation of CX3CR1 in circulating T cells are associated with the clinical benefit of anti‐PD‐1 in patients with SBA. Overall, these findings suggest that the frequency and cytolytic capacity of circulating, effector immune cells may differentiate clinical response to ICIs, providing a strong rationale to support immune monitoring using patient peripheral blood.
Provisional Reduction and External Fixation of Acute Displaced Intra-articular Calcaneus Fractures: Surgical Technique and Clinical Results
Yan, Alan Y. , Shafiq, Babar , Canton, Stephen P. , Olson, Joshua T., Cole, Peter Alexander

Mayo Clinic

Techniques in Foot & Ankle Surgery | March 23, 2022 | Volume: 22 | Issue: 1 | Pages: 35-43

10.1097/btf.0000000000000353 Get It

The treatment of calcaneus fractures has been a topic of ongoing debate with controversies regarding the best treatment options and algorithms. Sparse literature exists examining the role of external fixation in initial reduction and the maintenance of bony alignment. The authors describe a technique of a medially based 3-pin provisional external fixation for the treatment of a displaced intra-articular calcaneus fractures with the review of 26 patients with an average follow-up of 26 months. A fourth pin utilized in the case of tongue-type fractures is introduced as an important adjunct to this treatment paradigm. Level of Evidence: Diagnostic Level IV—therapeutic. See Instructions for Authors for a complete description of levels of evidence.
Social Media and Professional Development for Oncology Professionals
Chidharla, Anusha , Attai, Deanna J. , Drake, Emily K. , Londen, G. J. van , Subbiah, Ishwaria M. , Henry, Elizabeth , Murphy, Martina, Barry, Maura , Manochakian, Rami , Leyfman, Yan , Utengen, Audun , Attai, Deanna J , Drake, Emily K , van Londen, G J , Subbiah, Ishwaria M , Henry, Elizabeth , Barry, Maura M , Manochakian, Rami , Moerdler, Scott , Loeb, Stacy , Graff, Stephanie L , Leyfman, Yan , Thompson, Michael A , Markham, Merry J , Utengen, Audun , Loeb, Stacy , Graff, Stephanie L. , Thompson, Michael A, Markham, Merry Jennifer

Mayo Clinic

JCO Oncology Practice | March 21, 2022 | Volume: 18 | Issue: 8 | Pages: 566-571

10.1200/op.21.00761 | PMID 35312343 Get It

The use of social media continues to increase in health care and academia. Health care practice, particularly the oncologic field, is constantly changing because of new knowledge, evidence-based research, clinical trials, and government policies. Therefore, oncology trainees and professionals continue to strive to stay up-to-date with practice guidelines, research, and skills. Although social media as an educational and professional development tool is no longer completely new to medicine and has been embraced, it is still under-researched in terms of various outcomes. Social media plays several key roles in professional development and academic advancement. We reviewed the literature to evaluate how social media can be used for professional development and academic promotion of oncology professionals.